Published in Circulation on August 18, 2003
The immune system and cardiac repair. Pharmacol Res (2008) 3.42
Myocardial ischemia-reperfusion injury: a neglected therapeutic target. J Clin Invest (2013) 2.83
Post-infarct remodelling: contribution of wound healing and inflammation. Cardiovasc Res (2008) 1.80
Salivating for knowledge: potential pharmacological agents in tick saliva. PLoS Med (2008) 1.46
B lymphocytes trigger monocyte mobilization and impair heart function after acute myocardial infarction. Nat Med (2013) 1.43
Tailoring therapy to best suit ST-segment elevation myocardial infarction: searching for the right fit. CMAJ (2003) 1.39
Myocardial ischemia and reperfusion injury is dependent on both IgM and mannose-binding lectin. Am J Physiol Heart Circ Physiol (2009) 1.22
The complement system in ischemia-reperfusion injuries. Immunobiology (2012) 1.10
Enzyme estimates of infarct size correlate with functional and clinical outcomes in the setting of ST-segment elevation myocardial infarction. Curr Control Trials Cardiovasc Med (2005) 1.10
Role of the complement components C5 and C3a in a mouse model of myocardial ischemia and reperfusion injury. Ger Med Sci (2010) 1.05
Complement-mediated dysfunction of glomerular filtration barrier accelerates progressive renal injury. J Am Soc Nephrol (2008) 1.04
Mechanisms of complement activation, C4d deposition, and their contribution to the pathogenesis of antibody-mediated rejection. Transplant Rev (Orlando) (2009) 1.03
Myocardial salvage in acute myocardial infarction--challenges in clinical translation. J Mol Cell Cardiol (2011) 0.98
Stromal derived factor 1α: a chemokine that delivers a two-pronged defence of the myocardium. Pharmacol Ther (2014) 0.95
How can we cure a heart "in flame"? A translational view on inflammation in heart failure. Basic Res Cardiol (2013) 0.94
Complement activation and prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. Diabetes Care (2012) 0.91
The inflammatory response and cardiac repair after myocardial infarction. Korean Circ J (2009) 0.89
Acute myocardial infarction activates distinct inflammation and proliferation pathways in circulating monocytes, prior to recruitment, and identified through conserved transcriptional responses in mice and humans. Eur Heart J (2015) 0.87
Mesenchymal stromal cells in renal ischemia/reperfusion injury. Front Immunol (2012) 0.87
Complement component 3 is necessary to preserve myocardium and myocardial function in chronic myocardial infarction. Stem Cells (2014) 0.86
Nonantithrombotic medical options in acute coronary syndromes: old agents and new lines on the horizon. Circ Res (2014) 0.84
Treatment with the C5a receptor antagonist ADC-1004 reduces myocardial infarction in a porcine ischemia-reperfusion model. BMC Cardiovasc Disord (2010) 0.84
Complement activity and pharmacological inhibition in cardiovascular disease. Can J Cardiol (2006) 0.83
Infarct angioplasty: beyond stents and glycoprotein IIb/IIIa inhibitors. Heart (2005) 0.83
Humanized cobra venom factor decreases myocardial ischemia-reperfusion injury. Mol Immunol (2009) 0.82
Mannan-binding lectin in cardiovascular disease. Biomed Res Int (2014) 0.81
N-terminal pro-brain natriuretic peptide and the timing, extent and mortality in ST elevation myocardial infarction. Can J Cardiol (2006) 0.80
Complement activation: an emerging player in the pathogenesis of cardiovascular disease. Scientifica (Cairo) (2012) 0.80
No reflow phenomenon in percutaneous coronary interventions in ST-segment elevation myocardial infarction. Indian Heart J (2016) 0.79
Inflammation and thrombosis in cardiovascular disease. Curr Opin Hematol (2013) 0.79
Methods of creatine kinase-MB analysis to predict mortality in patients with myocardial infarction treated with reperfusion therapy. Trials (2013) 0.79
Cardiogenic shock--an inflammatory disease. Wien Klin Wochenschr (2006) 0.78
Conditioning the heart to prevent myocardial reperfusion injury during PPCI. Eur Heart J Acute Cardiovasc Care (2012) 0.78
The effect of weight loss on serum mannose-binding lectin levels. Clin Dev Immunol (2012) 0.78
Elevated serum levels of mannose-binding lectin and diabetic nephropathy in type 2 diabetes. PLoS One (2015) 0.77
Platelets and the complement cascade in atherosclerosis. Front Physiol (2015) 0.77
Coronary care medicine: it's not your father's CCU anymore. Trans Am Clin Climatol Assoc (2004) 0.76
Association between endogenous complement inhibitor and myocardial salvage in patients with myocardial infarction. Eur Heart J Acute Cardiovasc Care (2013) 0.76
Plasma-derived Extracellular Vesicles Contain Predictive Biomarkers and Potential Therapeutic Targets for Myocardial Ischemic (MI) Injury. Mol Cell Proteomics (2016) 0.76
Anticomplement therapy. Biologics (2008) 0.76
TLR2 modulates antibodies required for intestinal ischemia/reperfusion-induced damage and inflammation. J Immunol (2014) 0.76
A previously unrecognized role of C3a in proteinuric progressive nephropathy. Sci Rep (2016) 0.75
Why did the anti-C5 complement antibody pexelizumab not reduce infarct size but influence clinical outcomes positively when applied as adjunctive therapy to primary percutaneous coronary intervention? Circulation (2004) 0.75
Optimal Duration of Coronary Ligation and Reperfusion for Reperfusion Injury Study in a Rat Model. Acta Cardiol Sin (2016) 0.75
Complement factor 5 blockade reduces porcine myocardial infarction size and improves immediate cardiac function. Basic Res Cardiol (2017) 0.75
Possible role of complement factors and their inhibitors in the myocardial infarction: an immunohistochemical study. Cent Eur J Immunol (2014) 0.75
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J (2012) 18.18
Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2009) 18.03
Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2007) 17.85
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med (2015) 13.90
Universal definition of myocardial infarction. Circulation (2007) 11.69
2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2013) 10.24
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med (2015) 9.70
Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med (2012) 8.88
Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med (2006) 8.74
Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med (2015) 8.69
Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59
Third universal definition of myocardial infarction. Circulation (2012) 8.47
Third universal definition of myocardial infarction. Eur Heart J (2012) 7.98
2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2012) 7.94
Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2013) 7.70
2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2010) 7.54
2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation (2012) 6.94
Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J (2005) 6.86
Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med (2007) 6.79
Myocardial viability and survival in ischemic left ventricular dysfunction. N Engl J Med (2011) 6.65
Pathophysiology of coronary artery disease. Circulation (2005) 6.65
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med (2005) 5.28
Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA (2004) 5.11
Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet (2002) 5.04
2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation (2013) 5.02
Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med (2011) 4.81
Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J (2003) 4.70
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med (2012) 4.49
Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation (2003) 4.43
Appropriateness of percutaneous coronary intervention. JAMA (2011) 4.33
Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med (2013) 4.16
Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med (2012) 4.10
Impact of National Clinical Guideline recommendations for revascularization of persistently occluded infarct-related arteries on clinical practice in the United States. Arch Intern Med (2011) 3.73
2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2008) 3.70
2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2013) 3.63
Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation (2007) 3.62
2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Thorac Cardiovasc Surg (2014) 3.59
Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation (2004) 3.56
A randomized trial of transfer for primary angioplasty versus on-site thrombolysis in patients with high-risk myocardial infarction: the Air Primary Angioplasty in Myocardial Infarction study. J Am Coll Cardiol (2002) 3.52
Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. JAMA (2007) 3.48
Implantable cardioverter defibrillators in primary and secondary prevention: a systematic review of randomized, controlled trials. Ann Intern Med (2003) 3.43
Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J (2002) 3.36
Intravenous platelet blockade with cangrelor during PCI. N Engl J Med (2009) 3.31
Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation (2013) 3.25
Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med (2011) 3.20
Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation (2009) 3.18
Prognostic significance of the change in glucose level in the first 24 h after acute myocardial infarction: results from the CARDINAL study. Eur Heart J (2006) 3.14
Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. J Am Coll Cardiol (2002) 3.05
Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction. N Engl J Med (2002) 3.01
Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med (2014) 2.90
Impact of collateral flow to the occluded infarct-related artery on clinical outcomes in patients with recent myocardial infarction: a report from the randomized occluded artery trial. Circulation (2010) 2.88
Declining in-hospital mortality and increasing heart failure incidence in elderly patients with first myocardial infarction. J Am Coll Cardiol (2009) 2.82
Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol (2012) 2.77